Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCL2 expression + MYC expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3	lenalidomide + zanubrutinib Sensitive: C3 – Early Trials lenalidomide + zanubrutinib Sensitive : C3
BCL2 expression + MYC expression	Lymphoma	BCL2 expression + MYC expression	Lymphoma	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	CD20-targeted CAR-T immunotherapy + venetoclax Sensitive: D – Preclinical CD20-targeted CAR-T immunotherapy + venetoclax Sensitive : D	CD20-targeted CAR-T immunotherapy + venetoclax Sensitive: D – Preclinical CD20-targeted CAR-T immunotherapy + venetoclax Sensitive : D